secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001549595-25-000117
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix appoints former Pfizer oncology chief Roger Dansey to board
-----------------------------------------------------------------

- Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.
- Former Chief Development Officer and Chief Oncology Officer at Pfizer; previously CMO and interim CEO of Seagen.
- Initial stock option grant of 50,000 shares, vesting monthly over three years; pro rata annual retainer of $50,000.
- Dansey brings experience from leading Keytruda development at Merck and Xgeva at Amgen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000117/0001549595-25-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000117/nrix-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer